

PB 71 of 2025

National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025

*National Health Act 1953*

I, REBECCA RICHARDSON, as delegate of the Minister for Health and Ageing, make this determination under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the *National Health Act 1953*.

Dated 26 June 2025

REBECCA RICHARDSON

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division, Health Resourcing Group

Department of Health, Disability and Ageing

Contents

**1 Name** 3

**2 Commencement** 3

**3 Repeal** 3

**4 Authority** 3

**5 Definitions** 3

**Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day** 4

**6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1**  4

**7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items** 4

**8 Reduction Day** 4

**Part 2 – Brands of pharmaceutical items with a weighted average disclosed price** 4

**9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2** 4

**Schedule 1 –** Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day

**Schedule 2 –** Brands of pharmaceutical items with a weighted average disclosed price and no reduction day

## **1 Name**

1. This instrument is the *National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025*.
2. This instrument may also be cited as PB 71 of 2025.

## **2 Commencement**

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | The day after this instrument is registered. |  |

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## **3 Repeal**

The *National Health (Weighted average disclosed price – April 2025 reduction day) Determination 2024 (PB 146 of 2024)* is repealed.

## **4 Authority**

This instrument is made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the *National Health Act 1953*.

## **5 Definitions**

Note: A number of expressions used in this instrument are defined in section 99ADB of the Act, including the following:

(a) adjusted approved ex-manufacturer price;

(b) data collection period

(c) unadjusted price reduction;

(d) weighted average disclosed price.

In this instrument:

***Act*** means the *National Health Act 1953.*

# **Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day**

## **6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1**

(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 is the amount specified in column 3 of that table item.

(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 31 March 2025.

Note: Paragraph 99ADH(1)(a) of the Act applies if, under section 99ADB, the Minister determines the weighted average disclosed price of a brand of a pharmaceutical item in respect of a data collection period for the brand.

## **7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items**

The adjusted approved ex-manufacturer price of a brand of pharmaceutical item specified in column 2 of the table to Schedule 1 is the amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 6 of this instrument.

Note: Subsection 99ADB(7) of the Act provides that a determination made under subsection 99ADB(4) in relation to a brand of pharmaceutical item may include the adjusted approved ex-manufacturer price of the brand of pharmaceutical item.

## **8 Reduction Day**

For paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 has a reduction day of 1 October 2025.

# **Part 2 – Brands of pharmaceutical items with a weighted average disclosed price**

## **9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2**

(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 2 is the amount specified in column 3 of that table item.

(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 31 March 2025.

Note: This instrument does not determine a reduction day for paragraph 99ADH(1)(aa) of the Act for a brand.